New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on August 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph J Wolk, the Executive Vice President and Chief Financial Officer of Johnson & Johnson, recently executed a significant transaction by selling 16,820 shares of the company’s stock. This sale amounted to a substantial $2,975,458, reflecting a noteworthy financial move within the company’s executive ranks.
Recent Updates on JNJ stock
In the last 24 hours, Johnson & Johnson’s stock has seen significant developments following its Q2 earnings report and subsequent analyst actions. The company reported strong financial performance with a 5.8% increase in worldwide sales and an 18.2% rise in net earnings, driven by robust demand in its Innovative Medicine and MedTech segments. These results have led Erste Group to upgrade J&J to a Buy rating, citing the company’s higher operating margin and return on equity compared to competitors, as well as improved growth prospects. Additionally, J&J raised its full-year sales and EPS guidance, reflecting confidence in its future performance despite challenges such as the loss of exclusivity for STELARA and declines in the orthopedics segment. The oncology and cardiovascular segments showed particularly strong growth, contributing to the positive outlook. Overall, the company’s strategic focus on innovation and restructuring within its MedTech segment is expected to drive long-term shareholder value.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson receives a solid overall score of 77.8, driven primarily by its strong financial performance and positive earnings call. The company’s robust margins, steady growth, and raised guidance indicate a positive outlook, while technical indicators suggest short-term caution due to potential overbought conditions. Valuation metrics further support the stock’s attractiveness, offering an appealing dividend yield.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 24.18%
Average Trading Volume: 8,386,203
Technical Sentiment Signal: Buy
Current Market Cap: $425.4B